A Diagnostic for the Early Detection of Bladder Cancer
Study Details
Study Description
Brief Summary
To improve upon the non-invasive detection of bladder cancer by further validating a multiplex ELISA assay directed at a bladder cancer-associated diagnostic signature in voided urine samples of patients with a high risk of developing bladder cancer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
Environmental exposures, specifically tobacco smoke, increases the risk of many cancers, including bladder cancer. To date, there are no diagnostics capable of detecting bladder cancer early, that is prior to clinical presentation. Because of this severe limitation, nearly 30% of patients initially present with stage 2 and higher bladder cancer. Stage 2 bladder cancer has a 5-year survival of 50%, while stage 3/4 have a 5-year survival of <20%. Ideally, bladder cancer would be preventable. Unfortunate, this has not come to fruition. If these stage 2-4 bladder cancer cases could be detected at Stage 1 (5-yr survival >94%), then its possible to see an improvement in bladder cancer survival rates (21-23).
in this study, a urine-based diagnostic that possesses the potential to accurately identify patients who harbor bladder cancer prior to clinical manifestation will be tested.
Study Design
Outcome Measures
Primary Outcome Measures
- 1. To assess the ability to recruit and retain an appropriate high-risk group of subjects into a 5-year longitudinal study monitoring them for the development of bladder cancer. [5 years]
Ability to recruit
- 2. To report the sensitivity and specificity of the multiplex immunoassay ability to detect bladder cancer in patients with high risk of developing bladder cancer: males, >50 years and >40 pack year history of tobacco exposure. [5 years]
Performance of multiplex test in this study
- 3. To develop a prediction risk calculator from this cohort using cutting edge machine learning techniques (e.g., random forest) incorporating biomarker data and clinical data. [5 years]
Development of a risk calculator
Eligibility Criteria
Criteria
Inclusion Criteria:
Participants must be:
-
Age 50 years or older
-
Males
-
30 pack year history of tobacco exposure
-
Free of any malignancy except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years. Patients with localized prostate cancer who are being followed by an active surveillance program are also eligible.
-
Scheduled to be evaluated in the Pulmonary Rehab Clinic or Lung Cancer Screening Clinic
-
Willing and able to give written informed consent
-
Willing to provide voided urine sample
-
Be able and willing to complete semi-annual research clinic visits for 4 years
Exclusion Criteria:
Participants must not have:
-
History of hematuria (microscopic or gross) within 2 years of signing consent.
-
Previous history of bladder cancer
-
A known active urinary tract infection or urinary retention
-
An active stone disease (renal or bladder) or renal insufficiency (creatinine >2.0 mg/dL) - Serum creatinine value can be up to 2 years before consent, otherwise repeat.
-
An ureteral stents, nephrostomy tubes or bowel interposition
-
A recent genitourinary instrumentation (within 7 days prior to collection of voided urine sample)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Cedars-Sinai Medical Center | Los Angeles | California | United States | 90048 |
Sponsors and Collaborators
- Cedars-Sinai Medical Center
- Nonagen Bioscience Corporation
Investigators
- Principal Investigator: Hideki Furuya, Cedars-Sinai Medical Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IIT2021-19-Furyua-EarlyDx